Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - protac
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081 INVENTORS Sarki Abdulkadir (PI)* Gary Schiltz (PI)* SHORT DESCRIPTION A small molecule
PROTAC
technology that degrades DOT1L protein for targeted treatment of leukemia and prostate cancer. BACKGROUND Current cancer treatments, especially for MLL-rearranged leukemia and prostate cancer, face challenges of off-target effects and...
Published: 2/3/2026
|
Inventor(s):
Keywords(s):
Cancer/Oncology
,
Leukemia
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics.
NU 2020-217 (NU 2020-215, NU 2020-216, NU 2020-217) INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan Yu (Feinberg School of Medicine, Department of Medicine (Hematology & Oncology Division))* - **Now at Emory** SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (
PROTAC
) degraders...
Published: 2/3/2026
|
Inventor(s):
Keywords(s):
Bladder cancer
,
Breast cancer
,
Cancer/Oncology
,
Covalent inhibitor
,
Lymphoma
,
Melanoma
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics